Israel - Tiếng Anh - Ministry of Health

unipharm ltd, israel - bisoprolol hemifumarate - tablets - bisoprolol hemifumarate 2.5 mg - bisoprolol - bisoprolol - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.

Israel - Tiếng Anh - Ministry of Health

unipharm ltd, israel - bisoprolol hemifumarate - film coated tablets - bisoprolol hemifumarate 1.25 mg - bisoprolol - bisoprolol - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function (ejection fraction < 35%, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides

Israel - Tiếng Anh - Ministry of Health

unipharm ltd, israel - bisoprolol fumarate - tablets - bisoprolol fumarate 10 mg - bisoprolol - management of angina pectoris, hypertention. treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.

Israel - Tiếng Anh - Ministry of Health

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - tablets - atorvastatin as calcium trihydrate salt 10 mg - atorvastatin - atorvastatin - torva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable.pediatric patients (10-17 years of age) : torva is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.prevention of cardiovascular and/or cerebrovascular event such as mi or stroke: as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor.in patients with clinically evident coronary heart disease torva is indicated to:reduce the risk of non-fatal myocardial infarction.reduce the risk of fatal and non fatal stroke.reduce the risk for revascularization procedures.reduce the risk of hospitalization for chf.reduce the risk of angina.

Israel - Tiếng Anh - Ministry of Health

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - tablets - atorvastatin as calcium trihydrate salt 20 mg - atorvastatin - atorvastatin - torva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable.pediatric patients (10-17 years of age) : torva is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.prevention of cardiovascular and/or cerebrovascular event such as mi or stroke: as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor.in patients with clinically evident coronary heart disease torva is indicated to:reduce the risk of non-fatal myocardial infarction.reduce the risk of fatal and non fatal stroke.reduce the risk for revascularization procedures.reduce the risk of hospitalization for chf.reduce the risk of angina.

Israel - Tiếng Anh - Ministry of Health

unipharm ltd, israel - atorvastatin as calcium trihydrate salt - tablets - atorvastatin as calcium trihydrate salt 40 mg - atorvastatin - atorvastatin - torva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. torva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable.pediatric patients (10-17 years of age) : torva is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.prevention of cardiovascular and/or cerebrovascular event such as mi or stroke: as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor.in patients with clinically evident coronary heart disease torva is indicated to:reduce the risk of non-fatal myocardial infarction.reduce the risk of fatal and non fatal stroke.reduce the risk for revascularization procedures.reduce the risk of hospitalization for chf.reduce the risk of angina.

Israel - Tiếng Anh - Ministry of Health

unipharm ltd, israel - clomipramine hydrochloride - tablets - clomipramine hydrochloride 25 mg - non selective monoamine reuptake inhibitors - depression of varying origin.in children and adolescents there is not sufficient evidence of safety and efficacy of maronil in the treatment of depressive states of varying aetiology and symptomatology. the use of maronil in children and adolescents ( 0 - 17 years of age ) in this indication is therefore not recommended. obsessive compulcive syndromes.no experience is available in children younger than 5 years of age.

Israel - Tiếng Anh - Ministry of Health

unipharm ltd, israel - ezetimibe - tablets - ezetimibe 10 mg - ezetimibe - primary hypercholesterolemia: ezecor administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. homozygous familial hypercholesterolemia (hofh): ezecor administered with a statin are indicated for use in patients with hofh.patients may also receive adjunctive treatments (e.g. ldl apheresis).homozygous sitosterolemia (phytosterolemia): ezecor are indicated for use in patients with homozygous familial sitosterolemia.

Israel - Tiếng Anh - Ministry of Health

unipharm ltd, israel - amlodipine as maleate - tablets - amlodipine as maleate 10 mg - amlodipine - mild to moderate hypertension. vasospastic angina (prinzmetal's or variant angina). chronic stable angina.

Israel - Tiếng Anh - Ministry of Health

unipharm ltd, israel - amlodipine as maleate - tablets - amlodipine as maleate 5 mg - amlodipine - mild to moderate hypertension. vasospastic angina (prinzmetal's or variant angina). chronic stable angina.